# Harnessing scandium chelation chemistry for the development of radiopharmaceuticals

> **NIH NIH R01** · STATE UNIVERSITY NEW YORK STONY BROOK · 2022 · $360,571

## Abstract

The recent FDA-approval of 68Ga-imaging radiopharmaceuticals and their 177Lu-based companion therapeutics
underscores the potential of metallic radioisotopes for clinical applications in diagnostic and therapeutic nuclear
medicine. The improvements made to accelerator-based production of radiometals beyond the 68Ga, 177Lu
theranostic pair has opened opportunities to produce radiometals with a broad range of half-lifes and emission
properties, expanding the scope of imageable disease targets. However, subsequent development of clinically
applicable radiopharmaceuticals has been impeded by a significant gap in knowledge of aqueous coordination
chemistry of the corresponding metal ions. Scandium(III) aqueous chemistry represents a prime example of this
conundrum. 43Sc (Eβ+ avg = 476keV, t1/2= 3.9h) and 44Sc (Eβ+ avg = 632keV, t1/2= 4h) have ideal properties for
positron emission tomography (PET) imaging up to 24h post injection. For therapy applications, the emission
properties of 47Sc (Eβ− avg = 162keV, t1/2 = 80.4h) are comparable to 177Lu (Eβ− avg = 134keV, t1/2 = 159.6h). The
Sc(III) ion is a close chemical match to Lu(III) with respect to ionic radius and chemical hardness; therefore
43Sc/44Sc also represents an ideal diagnostic isotope partner to the already widely accessible 177Lu therapy
isotope, producing more directly predictive image-derived pharmacokinetics and dosimetry for radiotherapy.
However, the pronounced solution chemistry knowledge deficiency has hampered efficient separation, isolation,
and application of Sc(III) isotopes as clinical radiopharmaceuticals. To enable the synthesis of a broad range of
diagnostic and therapeutic radiopharmaceuticals based on Sc and Lu isotopes, we propose three aims towards
new chemical and in vivo validated strategies that enable high-yielding, high molar activity, low temperature
radiochemistry approaches to theranostic radiopharmaceuticals.

## Key facts

- **NIH application ID:** 10519845
- **Project number:** 1R01EB032349-01A1
- **Recipient organization:** STATE UNIVERSITY NEW YORK STONY BROOK
- **Principal Investigator:** Eszter Boros
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $360,571
- **Award type:** 1
- **Project period:** 2022-09-01 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10519845

## Citation

> US National Institutes of Health, RePORTER application 10519845, Harnessing scandium chelation chemistry for the development of radiopharmaceuticals (1R01EB032349-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10519845. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*